Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus
ConditionProgressive Keratoconus
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorGlaukos Corporation
About this trial
Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.
Eligibility criteria
Qualifiers
Provide written informed consent
Ability to hold gaze sufficiently stable for study testing
Willingness and ability to follow all instructions and comply with schedule for follow-up visits
Have a diagnosis of keratoconus
Disqualifiers
Known allergy or sensitivity to the test articles or components
Any disease causing abnormal topography other than keratoconus
Prior or current ocular condition (other than keratoconus) in the study eye that may predispose the eye for future complications
Trial design
Treatments tested in this trial
- NXL Energy 1
- NXL Energy 2
- NXL Energy 3
- Sham Treatment
Treatment groups
150 Participants
are divided into 8 treatment groups8
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov